血清补体C3、C4与慢性乙肝患者治疗效果的相关性分析(1)
【摘要】 目的：探讨血清补体C3、C4与慢性乙肝患者治疗效果的相关性分析。方法：选取本院2016年10月-2017年11月收治的慢性乙肝合并肝纤维化患者60例作为研究组，另选取同期健康体检者30例作为对照组。所有患者均给予恩替卡韦治疗。检测并比较两组治疗前后血清补体C3、C4水平、治疗前后患者肝功能指标、检测肝纤维化指标水平及血清补体C3、C4与肝功能、肝纤维化指标水平的相关性。结果：观察组治疗后血清补体C3、C4水平均较治疗前升高，差异均有统计学意义(P<0.05)；且观察组治疗后血清补体C3、C4水平与对照组比较，差异均无统计学意义(P>0.05)。随着肝炎活动度分级的增加血清补体C3、C4水平逐渐降低，差异均有统计学意义(P<0.05)。治疗后患者肝功能指标及肝纤维化指标均较治疗前改善，差异均有统计学意义(P<0.05)。血清补体C3、C4与治疗后肝功能指标、肝纤维化指标水平均呈负相关关系(P<0.05)。ROC曲线分析结果显示，血清补体C3、C4评价慢性乙肝患者治疗显效的评价价值良好。结论：血清补体C3、C4与慢性乙肝患者的治疗后肝功能密切相关，可作为治疗及疗效评价的辅助预测指标。
【关键词】 补体C3； 补体C4； 慢性乙肝； 肝纤维化
【Abstract】 Objective：To investigate the correlation analysis of the therapeutic effect of serum complement C3，C4 and chronic hepatitis B patients.Method：A total of 60 cases of chronic hepatitis B with liver fibrosis in our hospital from October 2016 to November 2017 were selected as the study group.In the same period，a total of 30 healthy people were selected as the control group.All patients were treated with Entecavir.The levels of serum complement C3 and C4 before and after treatment were detected and compared between the two groups. At the same time，the liver function indices，the indices of liver fibrosis，the correlation of their and serum complement C3，C4 were observed.Result：The levels of serum complement C3 and C4 in the observation group were higher than those before treatment(P<0.05)；there were no significant differences in the levels of serum complement C3 and C4 between the two groups after treatment(P>0.05).The levels of serum complement C3 and C4 were decreased with the increase of the degree of hepatitis activity.After treatment，the indices of liver function and liver fibrosis were better than those before treatment(P<0.05).The serum complement C3 and C4 were negatively correlated with the level of liver function index and the level of liver fibrosis(P<0.05).The results of ROC curve analysis showed that the evaluation value of serum complement C3 and C4 for the evaluation of chronic hepatitis B patients was good.Conclusion：The serum complement C3 and C4 are closely related to the liver function of the patients with chronic hepatitis B，can be used as an auxiliary predictor for the treatment and evaluation of the curative effect.
【Key words】 Complement C3； Complement C4； Chronic hepatitis B； Liver fibrosis
First-author’s address：Xili People’s Hospital of Shenzhen City，Shenzhen 518000，China
doi：10.3969/j.issn.1674-4985.2018.21.012
慢性乙型肝炎(chronic hepatitis B，CHB)是一种由乙型肝炎病毒(HBV)感染所致的在世界范围内最为常见的肝病类型之一，已成为我国的常见、多发疾病，对人民群众的身体健康及生命质量产生严重地威脅，而慢性乙肝合并肝纤维化的病情更不可忽视，如若肝纤维化指标长期处于较高水平，则患者有可能进入肝硬化趋势的危险，或加重肝硬化表现[1]。因此，抗肝纤维化治疗不仅可控制肝纤维化的发展，同时也是治疗慢性乙肝的一个重要手段，目前抗肝纤维化的治疗主要有针对原发病的治疗、抗肝脏炎症、促进胶原降解以及抑制胶原纤维形成等综合治疗[2-3]。既往对CHB患者的肝炎活动度及肝纤维化程度进行评价通常依靠肝组织病理学检查，但因进行肝活检易造成组织创伤，且不宜重复检查，并且在临床应用上存在一定的局限性，近年来，发现血清补体C3、C4与CHB不同肝损伤阶段具有相关性，进行生物学标志物研究对CHB病理学状态评估及治疗均具有重要的指导意义[4-5]。因此，本文探讨血清补体C3、C4与慢性乙肝合并肝纤维化患者治疗疗效的相关性分析，取得满意效果，现报道如下。, 百拇医药(鲁天瑜 黄红连 郑义 龚梅金)
【关键词】 补体C3； 补体C4； 慢性乙肝； 肝纤维化
【Abstract】 Objective：To investigate the correlation analysis of the therapeutic effect of serum complement C3，C4 and chronic hepatitis B patients.Method：A total of 60 cases of chronic hepatitis B with liver fibrosis in our hospital from October 2016 to November 2017 were selected as the study group.In the same period，a total of 30 healthy people were selected as the control group.All patients were treated with Entecavir.The levels of serum complement C3 and C4 before and after treatment were detected and compared between the two groups. At the same time，the liver function indices，the indices of liver fibrosis，the correlation of their and serum complement C3，C4 were observed.Result：The levels of serum complement C3 and C4 in the observation group were higher than those before treatment(P<0.05)；there were no significant differences in the levels of serum complement C3 and C4 between the two groups after treatment(P>0.05).The levels of serum complement C3 and C4 were decreased with the increase of the degree of hepatitis activity.After treatment，the indices of liver function and liver fibrosis were better than those before treatment(P<0.05).The serum complement C3 and C4 were negatively correlated with the level of liver function index and the level of liver fibrosis(P<0.05).The results of ROC curve analysis showed that the evaluation value of serum complement C3 and C4 for the evaluation of chronic hepatitis B patients was good.Conclusion：The serum complement C3 and C4 are closely related to the liver function of the patients with chronic hepatitis B，can be used as an auxiliary predictor for the treatment and evaluation of the curative effect.
【Key words】 Complement C3； Complement C4； Chronic hepatitis B； Liver fibrosis
First-author’s address：Xili People’s Hospital of Shenzhen City，Shenzhen 518000，China
doi：10.3969/j.issn.1674-4985.2018.21.012
慢性乙型肝炎(chronic hepatitis B，CHB)是一种由乙型肝炎病毒(HBV)感染所致的在世界范围内最为常见的肝病类型之一，已成为我国的常见、多发疾病，对人民群众的身体健康及生命质量产生严重地威脅，而慢性乙肝合并肝纤维化的病情更不可忽视，如若肝纤维化指标长期处于较高水平，则患者有可能进入肝硬化趋势的危险，或加重肝硬化表现[1]。因此，抗肝纤维化治疗不仅可控制肝纤维化的发展，同时也是治疗慢性乙肝的一个重要手段，目前抗肝纤维化的治疗主要有针对原发病的治疗、抗肝脏炎症、促进胶原降解以及抑制胶原纤维形成等综合治疗[2-3]。既往对CHB患者的肝炎活动度及肝纤维化程度进行评价通常依靠肝组织病理学检查，但因进行肝活检易造成组织创伤，且不宜重复检查，并且在临床应用上存在一定的局限性，近年来，发现血清补体C3、C4与CHB不同肝损伤阶段具有相关性，进行生物学标志物研究对CHB病理学状态评估及治疗均具有重要的指导意义[4-5]。因此，本文探讨血清补体C3、C4与慢性乙肝合并肝纤维化患者治疗疗效的相关性分析，取得满意效果，现报道如下。, 百拇医药(鲁天瑜 黄红连 郑义 龚梅金)